Daniel L. Kisner, Director at Conatus Pharmaceuticals Inc. (CNAT), bought 4,000 shares at $5.75 ($23K) on 2015-04-08, disclosed to the SEC on 2015-04-10.
Open-market purchase of $23k CNAT by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Something here stands out, but not much.
| Filing → |
| ONCT | BUY | 2020-07-23 | $24K | — | Filing → |
| DVAX | BUY | 2013-10-30 | $11K | — | Filing → |
| CALP | SELL | 2008-06-05 | $4K | — | Filing → |